Catalyst Pharmaceuticals Net Income
| CPRX Stock | USD 24.02 0.14 0.59% |
As of the 3rd of March, Catalyst Pharmaceuticals shows the Risk Adjusted Performance of 0.0229, mean deviation of 1.52, and Downside Deviation of 2.23. Catalyst Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Catalyst Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.8882 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 214.3 M | 225 M | |
| Net Income From Continuing Ops | 188.5 M | 197.9 M | |
| Net Income Applicable To Common Shares | 95.5 M | 100.3 M | |
| Net Income Per Share | 1.75 | 1.84 | |
| Net Income Per E B T | 0.76 | 1.03 |
Catalyst | Net Income | Build AI portfolio with Catalyst Stock |
The evolution of Net Income for Catalyst Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Catalyst Pharmaceuticals compares to historical norms and industry peers.
Latest Catalyst Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Catalyst Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Catalyst Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Catalyst Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Catalyst Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 214.33 M | 10 Years Trend |
|
Net Income |
| Timeline |
Catalyst Net Income Regression Statistics
| Arithmetic Mean | 45,586,958 | |
| Coefficient Of Variation | 182.70 | |
| Mean Deviation | 65,789,124 | |
| Median | (255,945) | |
| Standard Deviation | 83,286,490 | |
| Sample Variance | 6936.6T | |
| Range | 259M | |
| R-Value | 0.83 | |
| Mean Square Error | 2306.1T | |
| R-Squared | 0.69 | |
| Significance | 0.000038 | |
| Slope | 13,683,619 | |
| Total Sum of Squares | 110986.2T |
Catalyst Net Income History
Other Fundumenentals of Catalyst Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Catalyst Pharmaceuticals Net Income component correlations
Catalyst Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Catalyst Pharmaceuticals is extremely important. It helps to project a fair market value of Catalyst Stock properly, considering its historical fundamentals such as Net Income. Since Catalyst Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Catalyst Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Catalyst Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. Projected growth potential of Catalyst fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Catalyst Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.06) | Earnings Share 1.71 | Revenue Per Share | Quarterly Revenue Growth 0.076 | Return On Assets |
Understanding Catalyst Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Catalyst's accounting equity. The concept of intrinsic value - what Catalyst Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Catalyst Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Catalyst Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Catalyst Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Catalyst Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Catalyst Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Catalyst Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Catalyst Pharmaceuticals.
| 12/03/2025 |
| 03/03/2026 |
If you would invest 0.00 in Catalyst Pharmaceuticals on December 3, 2025 and sell it all today you would earn a total of 0.00 from holding Catalyst Pharmaceuticals or generate 0.0% return on investment in Catalyst Pharmaceuticals over 90 days. Catalyst Pharmaceuticals is related to or competes with Mineralys Therapeutics, Apellis Pharmaceuticals, Beam Therapeutics, Adaptive Biotechnologies, Scholar Rock, Ideaya Biosciences, and Recursion Pharmaceuticals. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing ... More
Catalyst Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Catalyst Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Catalyst Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.23 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 10.9 | |||
| Value At Risk | (3.56) | |||
| Potential Upside | 3.09 |
Catalyst Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Catalyst Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Catalyst Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Catalyst Pharmaceuticals historical prices to predict the future Catalyst Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0229 | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | (0.16) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0358 |
Catalyst Pharmaceuticals March 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0229 | |||
| Market Risk Adjusted Performance | 0.0458 | |||
| Mean Deviation | 1.52 | |||
| Semi Deviation | 2.12 | |||
| Downside Deviation | 2.23 | |||
| Coefficient Of Variation | 4599.75 | |||
| Standard Deviation | 2.04 | |||
| Variance | 4.18 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | (0.16) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0358 | |||
| Maximum Drawdown | 10.9 | |||
| Value At Risk | (3.56) | |||
| Potential Upside | 3.09 | |||
| Downside Variance | 4.97 | |||
| Semi Variance | 4.48 | |||
| Expected Short fall | (1.52) | |||
| Skewness | (0.71) | |||
| Kurtosis | 1.56 |
Catalyst Pharmaceuticals Backtested Returns
At this stage we consider Catalyst Stock to be very steady. Catalyst Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0412, which signifies that the company had a 0.0412 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Catalyst Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please confirm Catalyst Pharmaceuticals' Risk Adjusted Performance of 0.0229, downside deviation of 2.23, and Mean Deviation of 1.52 to double-check if the risk estimate we provide is consistent with the expected return of 0.0853%. Catalyst Pharmaceuticals has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.96, which signifies possible diversification benefits within a given portfolio. Catalyst Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Catalyst Pharmaceuticals is expected to follow. Catalyst Pharmaceuticals right now shows a risk of 2.07%. Please confirm Catalyst Pharmaceuticals potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Catalyst Pharmaceuticals will be following its price patterns.
Auto-correlation | 0.31 |
Below average predictability
Catalyst Pharmaceuticals has below average predictability. Overlapping area represents the amount of predictability between Catalyst Pharmaceuticals time series from 3rd of December 2025 to 17th of January 2026 and 17th of January 2026 to 3rd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Catalyst Pharmaceuticals price movement. The serial correlation of 0.31 indicates that nearly 31.0% of current Catalyst Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.31 | |
| Spearman Rank Test | 0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.23 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Catalyst Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Catalyst Pharmaceuticals reported net income of 214.33 M. This is 37.2% lower than that of the Biotechnology sector and 205.98% higher than that of the Health Care industry. The net income for all United States stocks is 62.46% higher than that of the company.
Catalyst Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Catalyst Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Catalyst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Catalyst Pharmaceuticals by comparing valuation metrics of similar companies.Catalyst Pharmaceuticals is currently under evaluation in net income category among its peers.
Catalyst Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Catalyst Pharmaceuticals from analyzing Catalyst Pharmaceuticals' financial statements. These drivers represent accounts that assess Catalyst Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Catalyst Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 699.9M | 1.9B | 1.8B | 2.9B | 2.6B | 2.7B | |
| Enterprise Value | 532.6M | 1.6B | 1.7B | 2.1B | 1.9B | 2.0B |
Catalyst Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Catalyst Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Catalyst Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Catalyst Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Catalyst Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Catalyst Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Catalyst Pharmaceuticals' value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-09-30 | 1.8 M | Arrowstreet Capital Limited Partnership | 2025-12-31 | 1.6 M | Charles Schwab Investment Management Inc | 2025-12-31 | 1.4 M | Boston Partners Global Investors, Inc | 2025-09-30 | 1.3 M | Northern Trust Corp | 2025-09-30 | 1.3 M | Amvescap Plc. | 2025-09-30 | 1.2 M | Kennedy Capital Management Inc | 2025-12-31 | 1.2 M | Millennium Management Llc | 2025-09-30 | 1.2 M | The Goldman Sachs Group Inc | 2025-09-30 | 1 M | Blackrock Inc | 2025-09-30 | 18.2 M | Vanguard Group Inc | 2025-12-31 | 8.4 M |
Catalyst Fundamentals
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.16 | ||||
| Profit Margin | 0.36 % | ||||
| Operating Margin | 0.41 % | ||||
| Current Valuation | 2.25 B | ||||
| Shares Outstanding | 122.91 M | ||||
| Shares Owned By Insiders | 6.45 % | ||||
| Shares Owned By Institutions | 88.80 % | ||||
| Number Of Shares Shorted | 9.59 M | ||||
| Price To Earning | 23.62 X | ||||
| Price To Book | 3.19 X | ||||
| Price To Sales | 4.98 X | ||||
| Revenue | 588.99 M | ||||
| Gross Profit | 489.03 M | ||||
| EBITDA | 321.01 M | ||||
| Net Income | 214.33 M | ||||
| Cash And Equivalents | 220.79 M | ||||
| Cash Per Share | 2.15 X | ||||
| Total Debt | 2.35 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 7.79 X | ||||
| Cash Flow From Operations | 208.67 M | ||||
| Short Ratio | 7.71 X | ||||
| Earnings Per Share | 1.71 X | ||||
| Target Price | 33.71 | ||||
| Number Of Employees | 182 | ||||
| Beta | 0.73 | ||||
| Market Capitalization | 2.94 B | ||||
| Total Asset | 1.1 B | ||||
| Retained Earnings | 474.19 M | ||||
| Working Capital | 502.93 M | ||||
| Current Asset | 59.9 M | ||||
| Current Liabilities | 3.44 M | ||||
| Net Asset | 1.1 B |
About Catalyst Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Catalyst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalyst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalyst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.